News &amp; Updates

Immunosuppression with prednisone plus either adalimumab or cyclosporine is effective in improving alopecia, but neither treatment does not provide any significant impact on the presence of vitiligo or poliosis in patients with Vogt-Koyanagi-Harada (VKH) disease at 6 months, reports a study.

Adalimumab vs cyclosporine: Which is better for dermatological symptoms in VKH disease?

No benefit to adding adjuvant chemo to hormonotherapy in high-risk breast cancer

Adding adjuvant chemotherapy to hormonotherapy does not appear to improve survival outcomes in older women with high-risk estrogen receptor (ER)-positive, HER2-negative breast cancer and is even associated with more adverse events, as shown in a phase III study.

No benefit to adding adjuvant chemo to hormonotherapy in high-risk breast cancer

Daridorexant benefits women with insomnia during menopausal transition

29 Aug 2025 by

Treatment with daridorexant improved sleep outcomes and daytime functioning in women with insomnia disorder during the menopausal transition, according to a study presented at EAN 2025.

Daridorexant benefits women with insomnia during menopausal transition

Steroidal mineralocorticoid receptor antagonist offers no CV mortality benefit in dialysis patients

Treatment with steroidal mineralocorticoid receptor antagonists does not appear to provide significant protection against cardiovascular mortality in patients undergoing dialysis, as shown in a systematic review and meta-analysis.

Steroidal mineralocorticoid receptor antagonist offers no CV mortality benefit in dialysis patients

Rituximab not superior to conventional therapy in EGPA

The use of rituximab falls short of demonstrating superiority over a conventional remission induction strategy in patients diagnosed with eosinophilic granulomatosis with polyangiitis (EGPA), reveals a study.

Rituximab not superior to conventional therapy in EGPA

Stapokibart makes the grade in severe chronic rhinosinusitis with nasal polyps

27 Aug 2025 by

In Asian patients with severe chronic rhinosinusitis with nasal polyps who are receiving daily intranasal corticosteroid, add-on treatment with the novel monoclonal antibody stapokibart helps shrink polyp size and bring down the severity of symptoms, as shown in the phase III CROWNS-2 study conducted in China.

Stapokibart makes the grade in severe chronic rhinosinusitis with nasal polyps

27 Aug 2025

Canagliflozin lowers HbA1c levels in children with T2DM

27 Aug 2025

Treatment with canagliflozin significantly reduces haemoglobin A1c (HbA1c) in children and adolescents with type 2 diabetes mellitus (T2DM), with a safety profile comparable to that seen in adults, results of a phase III trial have shown.

Canagliflozin lowers HbA1c levels in children with T2DM

27 Aug 2025

Prademagene zamikeracel promotes wound healing in rare genetic skin disease

In patients with large chronic wounds secondary to recessive dystrophic epidermolysis bullosa (RDEB), treatment with prademagene zamikeracel helps with wound healing and pain while being well tolerated, according to a phase III study.

Prademagene zamikeracel promotes wound healing in rare genetic skin disease

Light protection info lacking in package inserts of drugs: study

26 Aug 2025 by

A recent study in Singapore has found a lack of easily accessible detailed information on light protection in package inserts (PIs) of light-sensitive injectable drugs beyond the phrase “Protect from light.”

Light protection info lacking in package inserts of drugs: study

Sacubitril/valsartan outdoes standard therapy in BP reduction

Combination treatment with sacubitril and valsartan demonstrates greater efficacy than standard therapy in achieving blood pressure (BP) control and BP reduction in Afro-descendant patients with resistant hypertension, reports a study.

Sacubitril/valsartan outdoes standard therapy in BP reduction